Recurrent Head and Neck Carcinoma (DBCOND0058166)

Identifiers

Synonyms

Not Available

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT01638533	Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction	Romidepsin	treatment	1	active_not_recruiting
NCT02318771	Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer	Pembrolizumab	treatment	1	completed
NCT05980000	Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma	Pembrolizumab Ramucirumab	treatment	2	recruiting
NCT03049618	Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475	Pembrolizumab SEphB4-HSA	treatment	2	active_not_recruiting
NCT02646319	Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations	Albumin human Sirolimus	treatment	0	completed
NCT00954226	Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer	Erlotinib	treatment	1	active_not_recruiting
NCT03892720	Stereotactic Body Radiation Therapy Using HyperArc in Treating Patients With Recurrent Head and Neck Cancer	No drug interventions	treatment	Not Available	completed
NCT01727076	Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer	Interleukin-15, human recombinant	treatment	1	completed
NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	ABSK-091 Adavosertib Afatinib Binimetinib Capivasertib Copanlisib Crizotinib Dabrafenib Dasatinib Defactinib Erdafitinib GSK-2636771 Ipatasertib Larotrectinib Methane Nivolumab Osimertinib Palbociclib Pertuzumab Relatlimab Sapanisertib Sulfate ion Sunitinib Taselisib Trametinib Trastuzumab Trastuzumab emtansine Tyrosine Ulixertinib Vismodegib	screening	2	active_not_recruiting
NCT02706691	BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer	Infigratinib	treatment	2	terminated
NCT01846091	Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer	Measles virus vaccine live attenuated Sodium iodide	treatment	1	completed
NCT02474368	Study Evaluating a Stereotactic Boost/Treatment for Recurrent or Metastatic Cancer of the Head and Neck	Cisplatin	treatment	1	active_not_recruiting
NCT01696955	Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery	Cetuximab Tivantinib	treatment	2	completed
NCT03727061	Porfimer Sodium Interstitial Photodynamic Therapy With or Without Standard of Care Chemotherapy in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer	Nivolumab Porfimer sodium	treatment	1	recruiting
NCT03164460	Stereotactic Body Radiation Therapy or Intensity Modulated Radiation/Proton Therapy in Treating Patients With Recurrent Head and Neck Cancer	No drug interventions	treatment	2	recruiting
NCT06572423	Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy for Palliative Head and Neck Cancer Treatment (PULS-Pal)	No drug interventions	supportive_care	Not Available	not_yet_recruiting
NCT02467738	Surgical Resection and Intraoperative Cesium-131 Brachytherapy for Head and Neck Cancer	Cesium Cs-131	treatment	0	completed
NCT04514484	Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV	Cabozantinib Nivolumab	treatment	1	active_not_recruiting